26 related articles for article (PubMed ID: 8514444)
1. Direct LC-MS/MS Detection of Guanine Oxidations in Exon 7 of the p53 Tumor Suppressor Gene.
Jiang D; Malla S; Fu YJ; Choudhary D; Rusling JF
Anal Chem; 2017 Dec; 89(23):12872-12879. PubMed ID: 29116749
[TBL] [Abstract][Full Text] [Related]
2. Study of mutations in p53 tumour suppressor gene in human sporadic breast cancers.
Makwane N; Saxena A
Indian J Clin Biochem; 2009 Jul; 24(3):223-8. PubMed ID: 23105839
[TBL] [Abstract][Full Text] [Related]
3. Biological indices in the assessment of breast cancer.
Leong AS; Lee AK
Clin Mol Pathol; 1995 Oct; 48(5):M221-38. PubMed ID: 16696013
[No Abstract] [Full Text] [Related]
4. Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice.
Visscher DW; Sarkar FH; Crissman JD
J Clin Lab Anal; 1997; 11(1):10-6. PubMed ID: 9021519
[No Abstract] [Full Text] [Related]
5. Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis (F-SSCP).
Ellison JS
Mol Biotechnol; 1996 Feb; 5(1):17-31. PubMed ID: 8853013
[TBL] [Abstract][Full Text] [Related]
6. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas.
Pollina L; Pacini F; Fontanini G; Vignati S; Bevilacqua G; Basolo F
Br J Cancer; 1996 Jan; 73(2):139-43. PubMed ID: 8546897
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.
MacGrogan G; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
Breast Cancer Res Treat; 1995; 36(1):71-81. PubMed ID: 7579509
[TBL] [Abstract][Full Text] [Related]
9. Type and frequency of p53 mutations in tumors of the nervous system and its coverings.
Kleihues P; Ohgaki H; Eibl RH; Reichel MB; Mariani L; Gehring M; Petersen I; Höll T; von Deimling A; Wiestler OD
Recent Results Cancer Res; 1994; 135():25-31. PubMed ID: 8047694
[No Abstract] [Full Text] [Related]
10. The p53 tumor-suppressor gene in human breast cancer.
Allred DC; Elledge R; Clark GM; Fuqua SA
Cancer Treat Res; 1994; 71():63-77. PubMed ID: 7946959
[No Abstract] [Full Text] [Related]
11. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index.
Merlo GR; Bernardi A; Diella F; Venesio T; Cappa AP; Callahan R; Liscia DS
Int J Cancer; 1993 Jun; 54(4):531-5. PubMed ID: 8514444
[TBL] [Abstract][Full Text] [Related]
12. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations occur in aggressive breast cancer.
Mazars R; Spinardi L; BenCheikh M; Simony-Lafontaine J; Jeanteur P; Theillet C
Cancer Res; 1992 Jul; 52(14):3918-23. PubMed ID: 1617667
[TBL] [Abstract][Full Text] [Related]
14. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families.
Warren W; Eeles RA; Ponder BA; Easton DF; Averill D; Ponder MA; Anderson K; Evans AM; DeMars R; Love R
Oncogene; 1992 May; 7(5):1043-6. PubMed ID: 1570151
[TBL] [Abstract][Full Text] [Related]
15. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
